Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evident lawsuit

This article was originally published in The Rose Sheet

Executive Summary

U.S. Court of Appeals for Federal Circuit denies Evident Corporation's appeal Oct. 9 in patent infringement lawsuit firm filed against Church & Dwight and Colgate in June 1997. Court ruled Evident's U.S. Patent No. 4,971,782, which involves the manufacture of toothpaste formulated with baking soda and peroxide, was unenforceable. Claiming Church & Dwight and Colgate violated its patent in formulating baking soda and peroxide toothpastes, Evident was seeking royalties in excess of $45 mil., according to firm's attorney. Evident also appealed court's decision to grant attorney fees to Church & Dwight on July 23, 2003. Court is expected to hear the appeal within next few months, Church & Dwight says...

You may also be interested in...



US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Generic Oncology Drugs’ Safety Is Key Focus In US FDA Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.

UsernamePublicRestriction

Register

RS011578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel